INTRODUCTION
The urgent need to discover and develop new antibacterial agents to counter the threat of drug-resistant infections is widely recognised. Research efforts over the past few years have focused on the development of novel classes of antibacterials with a dual-targeting mechanism-of-action distinct from currently-used antibiotics, with the twin objectives of avoiding cross-resistance and reducing the emergence of de novo resistance. The essential bacterial type II topoisomerase enzymes, DNA gyrase and topoisomerase IV, are wellvalidated drug targets for antibiotic pharmacology as evidenced by the fluoroquinolone and aminocoumarin classes of antibiotics (5, 6, 7, 8) . These enzymes are responsible for introducing negative supercoils into DNA and for the decatenation of DNA. The high degree of sequence similarity between DNA gyrase and topoisomerase IV offers the prospect of multi-targeting with a single pharmacophore (9, 10) . Despite the now widespread resistance to the quinolones, the type II topoisomerases continue to provide opportunities for antibacterial discovery based on exploiting novel binding interactions between new chemical ligands and the target enzymes in order to bypass mutations associated with quinolone resistance. Selected examples of this strategy are the 2-aminoquinazolinedione (11), the isothiazoloquinolone (12) , the spiropyrimidinetrione (13) and the novel tricyclic topoisomerase inhibitor (NTTI) (14) classes.
One emerging class of non-quinolone inhibitors of DNA gyrase and topoisomerase IV is the Novel Bacterial Topoisomerase Inhibitor (NBTI) type. NBTI molecules bind to a site which is distinct from, but adjacent to, the catalytic centre of DNA gyrase/topoisomerase IV that is occupied by the quinolones (15) . Consequently, NBTI compounds retain potency against quinolone-resistant isolates. Structurally, NBTI molecules comprise a northern head group that interacts with the DNA, a central linker portion, and a southern group that binds to the enzymes. A number of advanced NBTI molecules have been described in the literature, including NXL101 (16) , AZD9742 (17) , NBTI 5463 (18) and gepotidacin (19) , which recently successfully completed phase II human clinical evaluation for the treatment of uncomplicated urogenital gonorrhea caused by Neisseria gonorrhoeae (NCT02294682). The NBTI pharmacophore, however, has been associated with cardiovascular and other safety liabilities (17, 20, 21, 22, 23) . A key aim in the development of NBTIs, therefore, is achieving broad antibacterial potency, including against challenging Gram-negative pathogens, whilst maintaining satisfactory safety margins.
Towards this goal, Redx Pharma recently disclosed a new series of NBTI type compounds characterised by a novel tricyclic northern head group as described in International Patent WO 2016/024096 (24) . The chemical structures of six selected compounds from this series are displayed in Figure 1 . The purpose of this present study was to undertake a detailed in vitro biological evaluation of exemplar compounds from the series. Specifically, their ability to inhibit DNA gyrase and topoisomerase IV activities; their whole-cell potency against panels of wild-type and quinolone-resistant bacteria, including clinically-important anaerobes and biodefence organisms; and their in vitro safety profiles were assessed and are reported. 35 mM Tris.HCl (pH 7.5), 24 mM KCl, 4 mM MgCl2, 2 mM DTT, 1.8 mM Spermidine, 1 mM ATP, 6.5 % (w/v) glycerol and 0.1 mg/ml BSA. E. coli topoisomerase IV decatenation reactions were conducted under the following conditions: 50 mM HEPES-KOH (pH 7.6), 100 mM potassium glutamate, 10 mM magnesium acetate, 10 mM dithiothreitol, 1 mM ATP and 50 μg/ml BSA. Inhibition of human topoisomerase II decatenation activity was assessed as 6 described previously (14) . Reactions were stopped using 30 μL chloroform/iso-amyl alcohol Whole-genome sequencing. Genomic DNA (gDNA) was extracted from the resistant strains using the PurElute Bacterial Genomic Kit (Edge BioSystems, Gaithersburg, Maryland). The gDNA was purified according to the manufacturer's instructions. Purified gDNA was used to create whole genome libraries using NEBNext Ultra kit and 150 bp paired end read sequence data were produced using an Illumina HiSeq 3000. Read data were stored as FASTQ files and then adaptor sequences were removed using cutadapt software (CHO) cell line using IonWorks patch clamp electrophysiology (29) .
MATERIALS AND METHODS

Reagents
LogD measurements. Partitioning of compounds between 1-octanol and 0.1 M phosphate buffer (pH 7.4) was measured using the shake-flask method (30) .
RESULTS
Inhibition of target activity in vitro.
The five compounds tested potently inhibited both E.
coli DNA gyrase and topoisomerase IV enzymes, consistent with a dual-targeting mechanism-of-action (Table 1) (Table 1) .
Bacterial susceptibility profile. Bacterial susceptibility profiling of the NBTI compounds
shows that the series has broad-spectrum activity against Gram-negative and Gram-positive pathogens tested, including those of the 'ESKAPE' group of microorganisms (Table 2) .
Compounds from the series were generally more potent against the Gram-positive species. Table 2 ). The exemplar compound REDX07638 was tested against a set of five biothreat microorganisms that included the aetiological agents of anthrax, Glanders, meliodosis, tularaemia and the plague ( anaerobius and C. perfringens with MIC90 values lower or equal to 2 µg/mL (Table 5) .
Metronidazole, however, was not active against P. acnes while the Redx compounds . By comparison, the frequency-of-resistance to ciprofloxacin at 4 × MIC was 7.8 × 10 -8 for E. coli ATCC 25922.
To confirm that the observed mutation frequencies were not species-specific, frequencies-of- were identified in all mutants (Table S1 ). Introduction of the single Arg38Leu mutation into E.
coli DNA gyrase led to a modest increase in IC50 of 10 to 17 fold for all compounds, with the exception of REDX06213 (no significant change in activity) in the enzyme assay (Table 1) .
However, whole-cell MIC testing revealed a loss in potency of 64-256 fold (Table S2 ).
In vitro safety profile. Mammalian cytotoxicity testing with the HepG2 cell line revealed IC50
values that were higher than the corresponding MIC values observed with the ESKAPE pathogens by more than two orders of magnitude (Table 6 ). In vitro testing showed the series to have a range of hERG inhibitory activity, with REDX07623 having an IC50 of 8.2
µM, whilst REDX6181 demonstrated reduced hERG inhibition with an IC50 >100 µM. A trend between logD and hERG activity was found with this series. Compounds with a lower logD appeared to have reduced hERG inhibition (Table 6) .
DISCUSSION
In recent years the growing threat of drug-resistant bacterial infections, combined with the lack of new antibiotics with a novel mechanism-of-action, has caused global concern.
Resistance of Gram-negative species to first line and last resort antibiotics has been reported worldwide and can lead to untreatable infections and increased mortality (35) . To (Table 1 ). This indicates that the NBTI series described here has a different mechanism-of-action to ciprofloxacin, which stabilises double-stranded broken DNA strands, blocking re-ligation, the consequences of which are poisonous to the bacterial cell. Instead, the NBTIs described here interact with the topoisomerase and DNA prior to double strand breakage, which has been reported for other NBTI series (18) .
Broad-spectrum antibacterial activity was found with this series against a panel of ESKAPE pathogens, the fastidious Gram-negative organisms H. influenzae and N. gonorrhoeae, as well as M. tuberculosis and important Gram-positive and Gram-negative biothreat pathogens (Table 2 and Development of resistance to other NBTI series at 4 × MIC has been reported in the literature. Resistance rates of 5 × 10 -8 were found with NBTI 5463 against P. aeruginosa PAO1, although sequencing showed no target gene mutations (18) . Second-and third-step mutants had Asp82Glu and Asp82Glu plus Asp87Tyr point mutations in GyrA, respectively (41) . These mutants showed no cross-resistance to the fluoroquinolones consistent with a differential binding mechanism between the NBTI and fluoroquinolone classes of topoisomerase inhibitors. Although no mutants were raised during the spontaneous frequency-of-resistance experiments against the compounds described here, whole genome sequencing of the E. coli REDX06276 serial passage mutant revealed a single Arg38Leu substitution in the GyrA subunit. This mutation has been reported previously and conferred resistance to 5, 6-bridged quinolones, but not to other quinolones (42) . Similarly, no crossresistance to ciprofloxacin was found with the E. coli REDX06276 serial passage mutant (Table S2) . To understand the contribution of the GyrA Arg38Leu substitution to the increased resistance of E. coli REDX06276, 4 Redx compounds were tested against the mutant gyrase in the supercoiling assay ( Table 1) . Introduction of the Arg38Leu mutation into the WT enzyme led to a modest increase in IC50 of 10 to 17 fold, except for REDX06213, which showed no significant change in activity. Whole-cell MIC testing revealed a loss in potency of 64-256 fold (Table S2) Introduction of more polar groups to reduce the logD of NBTI compounds has been shown to be associated with reduced hERG inhibition (22) . REDX06181 displayed the lowest logD of the compounds tested and showed the most attenuated hERG inhibition with an IC50 >100
µM. However, its antibacterial potency was reduced compared to other compounds with a higher logD, such as REDX07623. A negative correlation between whole-cell antibacterial potency and hERG inhibition has been reported for other NBTI type compounds (22) .
In summary, the NBTI series described here shows potent, balanced, dual-targeting inhibition of DNA gyrase and topoisomerase IV, with selectivity over human topoisomerase 
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FIGURE 1
Chemical structures of the compounds described in this study. 
